(BUSINESS WIRE )--Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYMETM in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HITTM) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma's commitment to meeting patient and injector needs in China.
In the past decade, the growth of China's aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.1 Developed using Galderma's proprietary OBTTM* gel technology, Restylane® VOLYMETM is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.2-3 Hyaluronic acid fillers are often patients' first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.
4 In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.1 “We are delighted to deliver Galderma's innovative aesthetics solutions in China with the support of our research and development teams, as well as local partners and regulatory authorities. As the Chinese market continues to expand, we look forward to working closely with all stakeholde.
